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Table 1. The percentage of afebrile patients at 24 h and 48 h after the first inhalation
of zanamivir.
Type of influenza
No. of
female
patients
No. of
male
patients
Age, mean
years  SD
No. (%) of
afebrile patients
At 24 h At 48 h
A (n p 67) 42 25 37.9  17.5 33 (49.3) 53 (79.1)
B (n p 100) 61 39 31.6  18.2 36 (36.0) 80 (80.0)
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Zanamivir Treatment Is
Equally Effective for Both
Influenza A and Influenza B
To the Editor—We previously reported
that oseltamivir was less effective against
influenza B than it was against influenza
A in a study of the 2002–2003 influenza
season; these findings were similar to those
in a report in 2007 by Sugaya et al. [1–3].
However, the effectiveness of another neu-
raminidase inhibitor, zanamivir, has not
been compared between influenza A and
influenza B. Therefore, we performed a
preliminary study of the effectiveness of
zanamivir for the treatment of 67 patients
with influenza A and 100 patients with
influenza B (with influenza being diag-
nosed using commercial antigen detection
kits) [3, 4] during the 2001–2002, 2002–
2003, 2003–2004, 2004–2005, and 2005–
2006 seasons (table 1). The percentage of
patients who were afebrile at 24 h or 48
h after the first inhalation of zanamivir was
analyzed as a parameter of the effective-
ness of zanamivir treatment. There was no
significant difference between patients
with influenza A and patients with influ-
enza B with respect to the percentage of
patients who were afebrile at 24 h (49.3%
vs. 36%) or at 48 h (79.1% vs. 80%).
In our previous study, the mean du-
ration of fever (SD) in patients with
influenza A and patients with influenza B
was h and h, re-31.2 23.7 47.1 30.8
spectively, after the first dose of oseltamivir
and h and h, re-47.9 26.0 65.4 32.8
spectively, after the onset of fever [3]. In
addition, the mean duration of fever
(SD) after onset of fever was 82.4
h and h in patients with36.0 78.3 41.9
influenza A and patients with influenza B,
respectively, who were not treated with an-
tiinfluenza drugs [3].
Studies of in vitro antiviral activity of
oseltamivir or zanamivir against labora-
tory strains of influenza virus that used
culture and enzymatic assays have sug-
gested that influenza B virus is less sus-
ceptible than influenza A virus to oselta-
mivir and zanamivir [5]. However, the
reported difference of the mean inhibitory
concentration of 50% between influenza
A and B viruses was less for zanamivir
(2.09 nM vs. 4.15 nM) than it was for
oseltamivir (0.73 nM vs. 11.53 nM). These
findings may explain our results in a clin-
ical context, showing that oseltamivir is
less effective against influenza B than it is
against influenza A and that zanamivir is
equally effective against both. We are now
studying the effectiveness of zanamivir
against influenza A and influenza B
among a large number of patients iden-
tified during the 2006–2007 season. In
conclusion, zanamivir is more effective
than oseltamivir for the treatment of in-
fluenza B.
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Halo Sign and Improved
Outcome
To the Editor—Greene et al. [1] de-
scribed baseline chest CT imaging findings
from 235 patients with invasive pulmo-
nary aspergillosis who participated in a
 at K
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niversiteit on July 10, 2012
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Figure 1. The evolution of CT images of invasive pulmonary aspergillosis in sequential CT scans
of the thorax, adapted from Caillot et al. [4]. The observed frequencies of the halo sign and the
air-crescent sign in a study by Greene et al. [1] are superimposed on the figure based on the study
by Caillot et al. [4].
previously published clinical trial that
compared the efficacy of voriconazole
therapy with that of amphotericin B ther-
apy [2]. The “typical” CT images associ-
ated with invasive fungal disease are the
halo sign and the air-crescent sign, which
were present in 60.9% and 10.2% of pa-
tients, respectively [1]. The authors de-
scribed 13 other image appearances that
are considered to be less specific for in-
vasive fungal disease. Interestingly, the
presence of a halo sign at baseline was
associated with a significantly higher
global response rate and better survival.
This difference in outcome was not ex-
plained by other factors, such as neutro-
penic status or underlying disease [1].
Caillot et al. [3, 4] noted that the halo
sign was the earliest radiological manifes-
tation of invasive pulmonary aspergillosis
in neutropenic patients and that nonspe-
cific images and the air-crescent sign be-
came more prevalent later in the course
of the disease (figure 1). Thus, the im-
proved outcome experienced among pa-
tients with a halo sign observed by Greene
et al. [1] could have been a result of the
earlier initiation of antifungal therapy in
the course of the fungal disease. This
would also explain why improved out-
come was observed regardless of whether
patients were treated with voriconazole or
amphotericin B.
Timing is crucial for successful therapy
of invasive Candida infections [5], because
the survival rate of patients treated im-
mediately after blood cultures were ob-
tained was better than that of patients in
whom administration of antifungal ther-
apy was delayed. There is no reason to
assume that the management of other in-
vasive fungal diseases would be any dif-
ferent. These observations underscore the
importance of reducing the delay in the
administration of effective treatment for
patients with invasive fungal infection.
As indicated in figure 1, the frequencies
of the halo sign and the air-crescent sign
encountered in the study by Greene et al.
[1] can be superimposed on the figure
based on the study by Caillot et al. [4] and
likely correspond with a delay in diagnosis
of∼72 h. Caillot et al. [4] obtained prompt
CT imaging of patients in whom invasive
aspergillosis was suspected, whereas the
current clinical practice is more in line
with the study by Greene et al. [1], in
which a delay of several days before a CT
was performed was not uncommon.
Given the importance of early initiation
of antifungal therapy, we should no longer
accept a delay in obtaining the diagnostic
information necessary for the optimum
treatment of patients with suspected in-
vasive fungal disease.
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Reply to Verweij et al.
To the Editor—Our thanks to Verweij
et al. [1] for their cogent comments. Al-
though data from our study [2] were not
sufficient to independently establish that
the patients in whom we identified a halo
 at K
atholieke U
niversiteit on July 10, 2012
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